The latest price target for GeneDx Hldgs (NASDAQ:WGS) was reported by Goldman Sachs on October 30, 2024. The analyst firm set a price target for $70.00 expecting WGS to fall to within 12 months (a possible -3.83% downside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for GeneDx Hldgs (NASDAQ:WGS) was provided by Goldman Sachs, and GeneDx Hldgs maintained their neutral rating.

There is no last upgrade for GeneDx Hldgs

There is no last downgrade for GeneDx Hldgs.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GeneDx Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GeneDx Hldgs was filed on October 30, 2024 so you should expect the next rating to be made available sometime around October 30, 2025.

While ratings are subjective and will change, the latest GeneDx Hldgs (WGS) rating was a maintained with a price target of $54.00 to $70.00. The current price GeneDx Hldgs (WGS) is trading at is $72.79, which is out of the analyst’s predicted range.